RESUMO
RESUMO Objetivo: Avaliar o efeito do colírio de brimonidina 0,2% na redução da hiperemia e do sangramento ocular durante as cirurgias de estrabismo, em comparação com o colírio de nafazolina 0,025% + feniramina 0,3%. Métodos: Foram avaliados 14 pacientes com estrabismo e indicação de correção cirúrgica bilateral. Foi instilado antes do procedimento, de forma aleatória, um colírio em cada olho dos pacientes avaliados. A análise subjetiva da hiperemia conjuntival e do sangramento perioperatório foi realizada de forma duplo-cega, por dois cirurgiões. A avaliação objetiva do nível de hiperemia conjuntival foi realizada por análise das imagens obtidas por meio do software ImageJ®. Resultados: A análise de modelos multivariados de efeito misto indicou diferenças estatisticamente significantes entre os grupos em relação à hiperemia (avaliador 2) e ao sangramento intraoperatório (avaliadores 1 e 2), com maiores escores nos casos tratados com colírio de nafazolina + feniramina. Entretanto, não houve diferença estatística na análise objetiva realizada por meio da saturação de cores obtidas pelo programa ImageJ®. Conclusão: O colírio de brimonidina pode ser superior ao colírio de nafazolina + feniramina na redução do sangramento, levando-se em conta apenas a análise subjetiva.
ABSTRACT Objective: To evaluate the effect of 0.2% brimonidine eye drops in reducing hyperemia and ocular bleeding during strabismus surgeries, in comparison with 0.025% naphazoline + 0.3% pheniramine eye drops. Methods: Fourteen patients with strabismus and indication for bilateral surgical correction were evaluated. Before the procedure, the eye drops were instilled randomly in each eye of the evaluated patients. The subjective analysis of conjunctival hyperemia and perioperative bleeding was performed in a double-blind manner, by 02 surgeons. The objective assessment of the level of conjunctival hyperemia was performed by analyzing the images obtained using the ImageJ® software. Results: The analysis of multivariate mixed effect models indicated statistically significant differences between the groups in relation to hyperemia (rater 2) and intraoperative bleeding (raters 1 and 2) with higher scores in cases treated with naphazoline + pheniramine eye drops. However, there were no statistically significant differences in the objective analysis of color saturation obtained by the ImageJ® program. Conclusion: Brimonidine eye drops may be superior to naphazoline + pheniramine eye drops in reducing bleeding, taking into account the subjective analysis only.
Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto , Feniramina/administração & dosagem , Hemorragia Ocular/prevenção & controle , Estrabismo/cirurgia , Tartarato de Brimonidina/administração & dosagem , Hiperemia/prevenção & controle , Complicações Intraoperatórias/prevenção & controle , Nafazolina/administração & dosagem , Soluções Oftálmicas/administração & dosagem , Pré-Medicação , Procedimentos Cirúrgicos Oftalmológicos/métodos , Vasoconstrição/efeitos dos fármacos , Fotografação , Método Duplo-Cego , Administração Tópica , Agonistas de Receptores Adrenérgicos alfa 2/administração & dosagem , Hemostasia Cirúrgica/métodosRESUMO
PURPOSE: To evaluate the efficacy of preoperative topical brimonidine use to maintain visibility during trabeculectomy and control intraoperative bleeding and postoperative subconjunctival hemorrhage. METHODS: The first group comprised 35 eyes of 34 patients administered brimonidine tartrate 0.15% (Brimogut, Bilim Ilac, Turkey) eye drops 6 and 3â min before surgery, and 33 eyes of 31 patients who received no medication for vasoconstriction formed the second group. Preoperative and postoperative photographs and operation video images were taken and vision analysis software used. Black-and-white images were obtained to identify the blood vessel and surface hemorrhage areas. The surface area of the hemorrhage was calculated by counting the black pixels with Image J software. RESULTS: There was no significant difference between two groups in terms of baseline (preoperative) eye redness (p > 0.05). In the first group, the eye redness values were 344.7 ± 19.5 pixels preoperatively and 244.1 ± 23.3 pixels at the beginning of the surgery, respectively (p < 0.001). However, no significant change was observed in the second group in eye redness (348.2 ± 17.5 pixels preoperatively and 360.7 ± 26.8 pixels at the beginning of the surgery, p > 0.05). Cautery was used for an average of 11.91 ± 1.96 s in the first group and 25.57 ± 4.66 s in the second to control intraoperative bleeding (P < 0.001). CONCLUSION: Preoperative topical brimonidine use in trabeculectomy surgery significantly decreased intraoperative bleeding and postoperative subconjunctival hemorrhage and facilitated bleeding control.
Assuntos
Doenças da Túnica Conjuntiva , Hemorragia Ocular , Trabeculectomia , Tartarato de Brimonidina , Doenças da Túnica Conjuntiva/tratamento farmacológico , Doenças da Túnica Conjuntiva/etiologia , Doenças da Túnica Conjuntiva/prevenção & controle , Hemorragia Ocular/tratamento farmacológico , Hemorragia Ocular/etiologia , Hemorragia Ocular/prevenção & controle , Humanos , Pressão Intraocular , Soluções Oftálmicas , Quinoxalinas/uso terapêuticoRESUMO
Purpose: In this study, we wanted to retrospectively evaluate the effect of the use of topical brimonidine on intraoperative bleeding and surgical hemostasis before strabismus surgery. Methods: Brimonidine tartrate 0.15% (Brimogut, Bilim Ilac, Turkey) eye drops were applied 6 and 3 min before surgery to 44 eyes of 22 patients in group 1 for vasoconstriction. Drops were not applied to 46 eyes of 23 patients in group 2. Preoperative and postoperative photographs and video images were taken. Black-and-white images were used to define the surface areas of the blood vessels. The surface area was calculated by counting the black pixels with ImageJ software. Results: In group 1, redness of eye was observed, on average, at preoperative 339.25 ± 11.52 pixels and intraoperative 247.93 ± 10.63 pixels (P < 0.001). But there was no change in group 2 (preoperative 338.87 ± 8.45 pixels to intraoperative 339.71 ± 9.52 pixels, P > 0.05). The incidence of intraoperative bleeding evaluated by the number of eyes on which cautery was used shows that it was significantly less in group 1 than in group 2 (P < 0.001). Conclusions: The use of topical brimonidine before strabismus surgery facilitates clear monitoring of anatomical structures during surgery by effectively controlling hemorrhage. In the postoperative period, it significantly reduces subconjunctival hemorrhage.
Assuntos
Agonistas de Receptores Adrenérgicos alfa 2/administração & dosagem , Tartarato de Brimonidina/administração & dosagem , Complicações Intraoperatórias/epidemiologia , Cuidados Pré-Operatórios/métodos , Estrabismo/cirurgia , Administração Tópica , Adolescente , Agonistas de Receptores Adrenérgicos alfa 2/efeitos adversos , Agonistas de Receptores Adrenérgicos alfa 2/farmacologia , Tartarato de Brimonidina/efeitos adversos , Tartarato de Brimonidina/farmacologia , Estudos de Casos e Controles , Criança , Doenças da Túnica Conjuntiva/epidemiologia , Doenças da Túnica Conjuntiva/patologia , Hemorragia Ocular/epidemiologia , Hemorragia Ocular/prevenção & controle , Feminino , Hemorragia/epidemiologia , Hemorragia/prevenção & controle , Hemostasia Cirúrgica , Humanos , Hiperemia/induzido quimicamente , Hiperemia/epidemiologia , Hiperemia/prevenção & controle , Incidência , Masculino , Soluções Oftálmicas , Fotografação/métodos , Período Pós-Operatório , Estudos Retrospectivos , Adulto JovemRESUMO
The use of antithrombotic therapy is rising as the population of older adults grows and novel agents with wider indications emerge. Likewise, surgical treatment of glaucoma may become increasingly common as the prevalence of glaucoma increases and innovative treatment options are developed. These trends highlight the need to understand how best to manage antithrombotic therapy in the context of glaucoma surgery. This review article describes current literature on antithrombotic therapy and perioperative thromboembolic risk evaluation based on individual factors. In addition, guidance is offered on the management of antithrombotic therapy in the setting of each type of glaucoma surgery, with an emphasis on a multidisciplinary approach involving the patients' treating physicians.
Assuntos
Anticoagulantes/uso terapêutico , Cirurgia Filtrante , Glaucoma/cirurgia , Inibidores da Agregação Plaquetária/uso terapêutico , Coagulação Sanguínea , Hemorragia Ocular/prevenção & controle , Humanos , Hifema/prevenção & controle , Trombose/tratamento farmacológicoRESUMO
OBJECTIVE: Subconjunctival hemorrhage (SCH) is an important minor side effect that might affect patient compliance to antivascular endothelial growth factor (anti-VEGF) intravitreal injection treatment (IVI). We sought to compare SCH incidence and pain score responses after topical oxymetazoline in naïve patients undergoing a single IVI of ranibizumab for diabetic macular edema. METHODS: Prospective, randomized, double-blinded, single centre study. One hundred two patients naïve to anti-VEGF were assigned to receive either topical oxymetazoline or placebo 30 minutes before IVI. SCH incidence and area were measured by slit lamp 24 hours after, and pain was evaluated 5 minutes and 24 hours after. RESULTS: SCH incidence was reported on 72% in control group versus 51% in oxymetazoline group (pâ¯=â¯0.037). Mean size of SCH was 16.82 mm2 in control group versus 12.55 mm2 in oxymetazoline group (pâ¯=â¯0.394). Prevalence of local pain in the overall study population was 60%. No significant statistical difference was achieved between groups 5 minutes or 24 hours after IVI in either pain scale evaluation. CONCLUSION: Administration of topical oxymetazoline 30 minutes before IVI is a single, harmless, cost-effective intervention that decreases the incidence of subconjunctival hemorrhage. This may considerably improve patient treatment satisfaction and promote compliance to IVI therapy.
Assuntos
Túnica Conjuntiva/irrigação sanguínea , Doenças da Túnica Conjuntiva/epidemiologia , Retinopatia Diabética/tratamento farmacológico , Hemorragia Ocular/prevenção & controle , Oximetazolina/administração & dosagem , Agonistas alfa-Adrenérgicos/administração & dosagem , Idoso , Doenças da Túnica Conjuntiva/diagnóstico , Doenças da Túnica Conjuntiva/prevenção & controle , Retinopatia Diabética/diagnóstico , Método Duplo-Cego , Hemorragia Ocular/diagnóstico , Hemorragia Ocular/epidemiologia , Feminino , Seguimentos , Humanos , Incidência , Injeções Intravítreas , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do TratamentoRESUMO
PURPOSE OF REVIEW: A large subset of patients with glaucoma uses anticlotting agents. No standardized guidelines currently exist for managing these agents in the specific perioperative setting of glaucoma surgery. The present review focuses on currently available anticlotting agents, their influence on hemorrhagic complications following glaucoma surgery, and management strategies for their use in the perioperative period RECENT FINDINGS: Anticlotting agents increase the risk of perioperative hemorrhagic complications following glaucoma surgery. Other factors that increase that risk have been identified as well, including the type of glaucoma surgery, preoperative intraocular pressure, postoperative hypotony, previous ocular surgeries, and race. Although general guidelines in the perioperative management of blood thinning agents exist, the best way to apply these guidelines specifically to glaucoma surgery remains unclear. SUMMARY: Blood thinners are widely used and can increase the risk of hemorrhagic complications in patients undergoing glaucoma surgery. Managing these agents in the perioperative setting is challenging and should be done in collaboration with the patient's primary care provider, hematologist, or cardiologist. Management strategies should be tailored to each individual's risk of hemorrhage versus thromboembolism. Additionally, surgical plans can be modified to help minimize hemorrhagic outcomes, especially in patients who are deemed to be at high risk for perioperative bleeding.
Assuntos
Anticoagulantes/efeitos adversos , Hemorragia Ocular/induzido quimicamente , Hemorragia Ocular/prevenção & controle , Glaucoma/cirurgia , Inibidores da Agregação Plaquetária/efeitos adversos , Anticoagulantes/uso terapêutico , Glaucoma/fisiopatologia , Humanos , Pressão Intraocular/fisiologia , Inibidores da Agregação Plaquetária/uso terapêutico , Tonometria OcularRESUMO
PurposeTo assess the risk of intraocular hemorrhage with warfarin and new oral anticoagulants (NOACs).MethodsWe ascertained all reported cases of intraocular hemorrhage (vitreous, choroidal, or retinal) with warfarin and NOACs (including dabigatran, rivaroxaban, apixaban) from the World Health Organizations's Vigibase database from 1968-2015. We used a disproportionality analysis to compute reported odds ratios (RORs) and corresponding 95% confidence by comparing the number of events with the study outcomes and study drugs compared with all other drugs reported to Vigibase. A harmful signal was deemed for a lower limit of the 95% confidence interval above 1.ResultsWe identified 80 cases of intraocular hemorrhage (vitreous, choroidal, or retinal) with warfarin in the World Health Organizations's Vigibase database from 1968-2015. A total of 156 cases of intraocular hemorrhage with NOACs (82 with rivaroxaban, 65 with dabigatran, 9 with apixaban). Warfarin had the highest signal of association with choroidal hemorrhage (ROR= 65.40 (33.86-126.30)). Rivaroxaban had the highest signal of association with both retinal and vitreous hemorrhage (ROR=7.41 (5.73-9.59) and ROR= 11.14 (7.37-16.86), respectively). Dabigatran was also significantly associated with retinal and vitreous hemorrhage (ROR= 3.78 (2.82-5.08) and ROR= 5.83 (3.66-9.30), respectively). The number of reports of retinal and vitreous hemorrhage were also significantly higher with apixaban, but the number of cases may be too little to make a meaningful evaluation.ConclusionA signal for risk of intraocular hemorrhage was detected for warfarin, dabigatran, and rivaroxaban. Large epidemiologic studies are needed to further confirm these findings.
Assuntos
Anticoagulantes/efeitos adversos , Hemorragia Ocular/induzido quimicamente , Hipertensão Ocular/induzido quimicamente , Acidente Vascular Cerebral/prevenção & controle , Anticoagulantes/administração & dosagem , Anticoagulantes/farmacocinética , Dabigatrana/efeitos adversos , Dabigatrana/farmacocinética , Hemorragia Ocular/prevenção & controle , Humanos , Razão de Chances , Pirazóis/efeitos adversos , Pirazóis/farmacocinética , Piridonas/efeitos adversos , Piridonas/farmacocinética , Fatores de Risco , Rivaroxabana/efeitos adversos , Rivaroxabana/farmacocinética , Acidente Vascular Cerebral/tratamento farmacológico , Varfarina/efeitos adversos , Varfarina/farmacocinéticaRESUMO
BACKGROUND: Atrial fibrillation (AF) affects 1%-2% of the general population and 13% of individuals older than 80 years of age. Anticoagulation has been the mainstay therapy to reduce stroke risk. Patients with previous intracranial hemorrhage (ICH) or intraocular hemorrhage (IOH) are at increased risk of recurrence if anticoagulation is continued or initiated. Left atrial appendage (LAA) closure may obviate the need for long-term anticoagulation in these patients. METHODS: We report our consecutive series of patients with nonvalvular AF with previous ICH or IOH who underwent LAA closure with the AMPLATZER Cardiac Plug (ACP; St Jude Medical, St Paul, MN), AMPLATZER Amulet, or WATCHMAN (Boston Scientific, Natick, MA) device. Demographics, clinical status, procedural outcomes, and complications were collected at baseline, during the procedure, at 3 months, at 1 year, and annually thereafter. RESULTS: Twenty-six patients with previous ICH (n = 24) or IOH (n = 2) underwent LAA closure (9 with the ACP, 3 with the Amulet, and 7 with the WATCHMAN). The mean age was 76 ± 7 years, and 61.5% were men with a mean CHADS2 (Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke/Transient Ischemic Attack) score of 3.2 ± 1.4 and CHA2DS2-VASc (Congestive Heart Failure, Hypertension, Age [≥ 75 years], Diabetes, Stroke/Transient Ischemic Attack, Vascular Disease, Age [65-74 years], Sex [Female] score) of 4.9 ± 1.7. No procedure-related complications occurred. Mean follow-up was 11.9 ± 13.3 months. One patient died at 13 months (this death was not related to the procedure), and 1 patient had a transient ischemic attack at 20.6 months after the procedure. No ischemic stroke, haemorrhagic stroke, or bleeding problems occurred during follow-up. CONCLUSIONS: In our consecutive series, LAA closure was found to be safe and effective in patients with AF and a history of ICH or IOH.
Assuntos
Apêndice Atrial/cirurgia , Fibrilação Atrial/cirurgia , Procedimentos Cirúrgicos Cardíacos/métodos , Hemorragia Ocular/prevenção & controle , Hemorragias Intracranianas/prevenção & controle , Idoso , Apêndice Atrial/diagnóstico por imagem , Fibrilação Atrial/complicações , Fibrilação Atrial/diagnóstico por imagem , Colúmbia Britânica/epidemiologia , Ecocardiografia Transesofagiana , Hemorragia Ocular/etiologia , Feminino , Seguimentos , Humanos , Incidência , Hemorragias Intracranianas/etiologia , Masculino , Taxa de Sobrevida/tendências , Resultado do TratamentoAssuntos
Anticoagulantes/uso terapêutico , Extração de Catarata , Hemorragia Ocular/prevenção & controle , Fibrinolíticos/uso terapêutico , Inibidores da Agregação Plaquetária/uso terapêutico , Hemorragia Pós-Operatória/prevenção & controle , Anestesia/efeitos adversos , Anestesia/métodos , Anticoagulantes/administração & dosagem , Catarata/complicações , Contraindicações , Hemorragia Ocular/induzido quimicamente , Hemorragia Ocular/etiologia , Fibrinolíticos/efeitos adversos , Humanos , Coeficiente Internacional Normatizado , Inibidores da Agregação Plaquetária/efeitos adversos , Hemorragia Pós-Operatória/induzido quimicamente , Guias de Prática Clínica como Assunto , Medição de Risco , Trombofilia/complicações , Trombofilia/tratamento farmacológicoRESUMO
The changing profile of patients undergoing ophthalmic surgery, with an increase in prevalence of antiplatelet and anticoagulant drug use, predisposes to bleeding complications. This mandates an awareness of these agents, allowing optimal patient management. We review traditional and newer agents in the context of cataract, vitreoretinal, glaucoma and oculoplastic surgery. Recommendations are given for continuation, cessation and re-commencement of these agents in order to minimise the risk of bleeding and thrombotic/thromboembolic complications.
Assuntos
Anticoagulantes/administração & dosagem , Hemorragia Ocular/prevenção & controle , Fibrinolíticos/administração & dosagem , Procedimentos Cirúrgicos Oftalmológicos , Assistência Perioperatória , Inibidores da Agregação Plaquetária/administração & dosagem , Hemorragia Pós-Operatória/prevenção & controle , Oftalmopatias/cirurgia , Humanos , Fatores de RiscoRESUMO
BACKGROUND: To investigate the haemostatic efficacy and histopathological effects of a new haemostatic agent, ankaferd blood stopper, in a rat conjunctival incision model. METHODS: Twenty Wistar albino rats were divided into two equal groups (A, B). Limbal incisions of 90-120° were performed in both eyes of all rats. In group A, bleeding at the site of incision was controlled by the administration of ankaferd blood stopper to the right eyes and balanced salt solution to the left eyes. In group B, bleeding was controlled by the application of ankaferd blood stopper to the right eyes and cautery to the left eyes. Time to haemostasis was recorded. After a 4-week period, conjunctival vascularity and postoperative adhesion between Tenon's capsule and sclera were assessed. Additionally, eyes were enucleated and evaluated histopathologically. RESULTS: In group A, the mean bleeding times were 15.2 and 66.7 s for right and left eyes, respectively (P = 0.002). In group B, the mean bleeding times were 17.6 and 17.5 s for right and left eyes, respectively (P = 0.939). Cautery was found to cause significantly more adhesion (P = 0.04). Histopathological examination of the conjunctiva and scleral revealed no statistically significant difference between the samples. CONCLUSIONS: Given the ease of use and lack of histopathological side-effects in the conjunctival incision model, ankaferd blood stopper is promising for use in ophthalmic surgery. Ankaferd blood stopper is a potent haemostatic agent. Its use in ophthalmic surgery should be investigated further in a larger cohort of patients and tested in clinical and experimental models.
Assuntos
Perda Sanguínea Cirúrgica/prevenção & controle , Túnica Conjuntiva/cirurgia , Hemorragia Ocular/prevenção & controle , Procedimentos Cirúrgicos Oftalmológicos/efeitos adversos , Extratos Vegetais/administração & dosagem , Animais , Túnica Conjuntiva/irrigação sanguínea , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Hemorragia Ocular/etiologia , Masculino , Soluções Oftálmicas , Ratos , Ratos Wistar , Resultado do TratamentoRESUMO
PURPOSE: Brimonidine (0.15%), which is used to lower intraocular pressure, is an α-2-adrenergic agonist that has vasoconstrictive effects. This study examined whether the administration of brimonidine (0.15%) before intravitreal injection prevents subconjunctival hemorrhage. METHODS: A prospective, randomized, double-masked single-center study. Two hundred and forty-four patients (244 eyes) who underwent intravitreal injection were prospectively examined. The control group (118 eyes) was given normal saline, while the experimental group received 0.15% brimonidine (126 eyes) 30 minutes before the intravitreal injection. On Days 1 and 7, the treatment outcome was assessed using slit-lamp microscopy. The severity of subconjunctival hemorrhage was scored on a scale of 1 (mild) to 3 (severe). To determine the size of the affected area, the lengths of the short and long axes of the subconjunctival hemorrhage were measured in millimeters and then multiplied. To consider both the severity and the size of subconjunctival hemorrhage, the severity score was multiplied by the size of the subconjunctival hemorrhage. RESULTS: Subconjunctival hemorrhage occurred as a result of intravitreal injection in 13.5% (17 eyes) of the brimonidine group and in 29.7% (35 eyes) of the control group (P = 0.003). On Days 1 and 7, the severity and size of the subconjunctival hemorrhage and the product of these 2 parameters were significantly lower in the brimonidine group. CONCLUSION: The administration of 0.15% brimonidine before an intravitreal injection decreased the incidence, severity, and size of subconjunctival hemorrhage.
Assuntos
Agonistas de Receptores Adrenérgicos alfa 2/administração & dosagem , Doenças da Túnica Conjuntiva/prevenção & controle , Hemorragia Ocular/prevenção & controle , Quinoxalinas/administração & dosagem , Administração Tópica , Tartarato de Brimonidina , Método Duplo-Cego , Feminino , Humanos , Pressão Intraocular/efeitos dos fármacos , Injeções Intravítreas , Masculino , Pessoa de Meia-Idade , Estudos ProspectivosAssuntos
Anticoagulantes/uso terapêutico , Extração de Catarata , Fidelidade a Diretrizes/normas , Oftalmologia/normas , Padrões de Prática Médica/estatística & dados numéricos , Varfarina/uso terapêutico , Hemorragia Ocular/prevenção & controle , Pesquisas sobre Atenção à Saúde , Humanos , Coeficiente Internacional Normatizado , Auditoria Médica , Assistência Perioperatória , Guias de Prática Clínica como Assunto , Sociedades Médicas/normas , Inquéritos e Questionários , Reino UnidoAssuntos
Agonistas alfa-Adrenérgicos/efeitos adversos , Ceratomileuse Assistida por Excimer Laser In Situ , Lasers de Excimer/uso terapêutico , Complicações Pós-Operatórias , Quinoxalinas/efeitos adversos , Retalhos Cirúrgicos , Deiscência da Ferida Operatória/induzido quimicamente , Agonistas alfa-Adrenérgicos/administração & dosagem , Tartarato de Brimonidina , Doenças da Túnica Conjuntiva/prevenção & controle , Substância Própria/patologia , Hemorragia Ocular/prevenção & controle , Humanos , Miopia/cirurgia , Quinoxalinas/administração & dosagem , Fatores de Risco , Deiscência da Ferida Operatória/patologia , Acuidade VisualRESUMO
An 11-item questionnaire was mailed to 891 consultant members of the Royal College of Ophthalmologists (RCOphth) to audit compliance with RCOphth guidelines for perioperative management of anticoagulated patients having cataract surgery. Four hundred ninety-nine questionnaires were analyzed. The results showed that 29.5% of respondents adhered to all aspects of RCOphth guidelines; that is, they checked the international normalized ratio (INR) preoperatively, continued warfarin, operated within the desired therapeutic INR range for the condition that warfarin was being used to treat (as set by the treating physician), and considered sub-Tenon or topical anesthesia in anticoagulated patients.
Assuntos
Anticoagulantes/uso terapêutico , Fidelidade a Diretrizes/normas , Oftalmologia/normas , Padrões de Prática Médica/estatística & dados numéricos , Varfarina/uso terapêutico , Extração de Catarata , Hemorragia Ocular/prevenção & controle , Pesquisas sobre Atenção à Saúde , Humanos , Coeficiente Internacional Normatizado , Auditoria Médica , Assistência Perioperatória , Guias de Prática Clínica como Assunto , Sociedades Médicas/normas , Inquéritos e Questionários , Reino UnidoRESUMO
PURPOSE: To assess the risks of intraoperative and postoperative bleeding associated with cataract extraction without prophylactic treatment in patients with severe factor XI (FXI) deficiency. DESIGN: Prospective interventional case series. SETTING: Single institute. STUDY POPULATION: Consecutive unrelated patients with severe FXI deficiency who underwent cataract extraction under topical anesthesia, with a clear corneal incision, phacoemulsification, and implantation of a foldable posterior chamber intraocular lens (PCIOL) were enrolled. Patients with associated intraocular conditions that could complicate the surgery were excluded. INTERVENTION: Cataract extraction without prophylactic treatment for the FXI deficiency. MAIN OUTCOME MEASURES: Assessment of intraoperative and postoperative ocular bleeding and other related complications. RESULTS: Seven patients ranging in age from 61 to 95 years (median, 79) underwent phacoemulsification and PCIOL implantation in 11 eyes. Five patients (71%) were homozygotes for type II mutation of the FXI gene (activity level of <1 U/dl), 1 patient was a homozygote for type III mutation (activity level of 11 U/dl), and 1 patient was a compound heterozygote for types II and III (activity level of 3 U/dl). Three of the patients (43%), all type II homozygotes, also had an inhibitor antibody to FXI. All 7 patients were followed for at least 1 week after the operation. The surgery was uneventful in all eyes, and neither major nor minor bleeding events were observed in any of the operated eyes during surgery and follow-up. CONCLUSIONS: Cataract extraction by phacoemulsification in uncomplicated eyes can be performed safely without prophylactic treatment in patients with severe FXI deficiency with or without inhibitor antibodies against FXI.
Assuntos
Perda Sanguínea Cirúrgica/prevenção & controle , Hemorragia Ocular/prevenção & controle , Deficiência do Fator XI/cirurgia , Implante de Lente Intraocular , Facoemulsificação , Hemorragia Pós-Operatória/prevenção & controle , Idoso , Idoso de 80 Anos ou mais , Fator XI/genética , Fator XI/imunologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Estudos Prospectivos , Tempo de Protrombina , Medição de RiscoRESUMO
PURPOSE: To determine whether brimonidine 0.2% minimizes the occurrence of subconjunctival hemorrhages without inducing postoperative flap complications in femtosecond laser in situ keratomileusis (LASIK). SETTING: Centro Oftalmológico Marqués de Sotelo and Hospital NISA Virgen del Consuelo, Valencia, Spain. METHODS: This prospective contralateral-eye interventional study evaluated consecutive patients who had bilateral simultaneous femtosecond LASIK for myopia (spherical equivalent [SE] range -1.00 to -8.00 diopters) performed with an IntraLase femtosecond laser and a Visx Star 2 excimer laser. One eye of each patient received a single drop of brimonidine tartrate 0.2% (brimonidine group) and the other eye, a single drop of a balanced salt solution (control group). RESULTS: The study evaluated 136 eyes (68 patients). The difference in the incidence of subconjunctival hemorrhages was statistically significantly lower in the brimonidine group (mean score 2.24 +/- 1.96 [SD]) than in the control group (mean score 7.61 +/- 2.72) (P<.001). However, no eye in the control group and 7 eyes (10.4%) in the brimonidine group had a dislocated flap with folds on the first postoperative day (P = .016). All eyes with dislocated flaps required surgical intervention. At 6 months, there was no significant difference between groups in the percentage of eyes achieving 20/20 or better uncorrected distance visual acuity, in the mean SE, or in the enhancement rate. CONCLUSIONS: Brimonidine prevented the formation of subconjunctival hemorrhages after femtosecond LASIK but increased the risk for flap dislocation. Thus, surgeons are cautioned against the use of perioperative brimonidine to decrease hemorrhagic complications in femtosecond LASIK.